secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sage Therapeutics, Inc. (—)
CIK:        0001597553
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001193125-25-170187
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 5.01, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus completes acquisition of Sage Therapeutics for $8.50/share plus CVR
----------------------------------------------------------------------------

- Tender offer expired with 36.3M shares (58%) tendered; all conditions satisfied.
- Shareholders receive $8.50 cash per share plus up to $3.50 per share CVR.
- Shares to be delisted from Nasdaq; company will file Form 15 to terminate registration.
- All prior directors and officers resigned; replaced by Supernus designees including Jack Khattar.
- CEO Barry Greene's severance amended with 18-month pay and 24-month non-compete covenant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597553/000119312525170187/0001193125-25-170187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597553/000119312525170187/d877271d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-170187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer